The inhalation company Inhalation Sciences has received an order for the PreciseInhale platform worth approximately SEK 1.76 million from an international distributor for the US market, with a global pharmaceutical company as the end customer. This is stated in a press release.The order represents an expansion of the company's operations and technology into the important US market, where new regulatory requirements are increasing demand for advanced in vitro methods for inhaled drugs. The US is a priority market for Inhalation Sciences."We are pleased to secure this significant order and collaborate with a leading global pharmaceutical company in the US. It marks an exciting expansion of PreciseInhale in North America, comments CEO Manoush Masarrat.